Ovarian Cancer

OVArian TUmor REsponse ('OVATURE') Trial Enrolls First U.S. Patient

Published in Drug Week, June 22nd, 2007

Researchers at the Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center (UTSMC) have enrolled the first U.S. patient in the worldwide clinical trial looking at oral phenoxodiol in combination with carboplatin for the treatment of recurring ovarian cancer.

Phenoxodiol has been shown in laboratory testing to be successful in restoring sensitivity of cancer cells from patients with ovarian cancer who have become resistant to standard chemotherapy drugs.

At UTSMC, the OVATURE trial will be led by John Schorge, MD, Associate Professor of gynecologic oncology.

"Earlier clinical studies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2007-06-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry